ORCA-2: A phase I study of olaparib in addition to cisplatin-based concurrent chemoradiotherapy for patients with high risk locally advanced squamous cell carcinoma of the head and neck.

Martin Forster,R. Mendes,Kevin J. Harrington,Teresa Guerrero-Urbano,Helen Baines,Victoria J. Spanswick,Leah Ensell,John A. Hartley,Sola Adeleke,Paul Gougis,David Leader,Cathy McDowell,Andre Lopes,Jonathan Teague,Sharon Forsyth,Sandy Beare

ORCA-2: A phase I study of olaparib in addition to cisplatin-based concurrent chemoradiotherapy for patients with high risk locally advanced squamous cell carcinoma of the head and neck.

2016

Martin Forster
R. Mendes
Kevin J. Harrington
Teresa Guerrero-Urbano
Helen Baines
Victoria J. Spanswick
Leah Ensell
John A. Hartley
Sola Adeleke
Paul Gougis
David Leader
Cathy McDowell
Andre Lopes
Jonathan Teague
Sharon Forsyth
Sandy Beare

TPS6108Background: Standard care for locally advanced squamous cell carcinoma of the head and neck (HNSCC) is cisplatin-based chemoradiotherapy (C-CRT). Use of intensity modulated radiotherapy (IMR...

Keywords:

Carcinoma
Cisplatin
Cancer research
Olaparib
Pathology
Chemoradiotherapy
Medicine
phase i study
basal cell
head and neck
Internal medicine
Oncology
locally advanced
concurrent chemoradiotherapy

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations